종양학 바이오시밀러 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 약물 종류별, 암 종류별, 유통 경로별, 지역별, 경쟁별(2020-2030년)
Oncology Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Type of Cancer, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1878898
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 종양학 바이오시밀러 시장은 2024년에 45억 4,000만 달러로 평가되었으며, 2030년까지 CAGR 6.94%로 성장하여 67억 9,000만 달러에 달할 것으로 예측됩니다.
종양학 바이오시밀러는 승인된 오리지널 종양학 생물학적 제제와 안전성, 순도, 효능에 있어 임상적으로 의미 있는 차이를 보이지 않는 것으로 입증된 생물학적 제제입니다. 시장 확대는 기본적으로 다양한 암 유형의 전 세계 발생률 증가와 수많은 블록버스터 암 생물학적 제제의 특허 만료가 임박함에 따라 저비용 대체품에 대한 기회가 생겨나고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
45억 4,000만 달러
시장 규모 : 2030년
67억 9,000만 달러
CAGR : 2025-2030년
6.94%
가장 빠르게 성장하는 부문
폐암
최대 시장
북미
주요 시장 촉진요인
주요 시장 과제
주요 시장 동향
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
약물 종류별(단클론항체, G-CSF, 조혈제, 기타)
암종별(유방암, 폐암, 위암, 전립선암, 자궁경부암, 혈액암, 뇌종양, 기타)
유통 채널별(소매 약국, 병원 약국, 온라인 약국)
지역별
기업별(2024)
시장 맵
제6장 북미의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 종양학 바이오시밀러 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 종양학 바이오시밀러 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
Teva Pharmaceuticals Industries Ltd.
STADA Arzneimittel AG
Shanghai Henlius Biotech, Inc.
Sandoz Group AG
Samsung Bioepis NL B.V.
Pfizer Inc.
Ligand Pharmaceuticals Inc.
Mylan Inc.
Innovent Biologics(USA), Inc.
Celltrion Inc.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Oncology Biosimilars Market, valued at USD 4.54 Billion in 2024, is projected to experience a CAGR of 6.94% to reach USD 6.79 Billion by 2030. Oncology biosimilars are biological products demonstrably highly similar to an approved original oncology biological product, exhibiting no clinically meaningful differences regarding safety, purity, and potency. The market's expansion is fundamentally driven by the increasing global incidence of various cancer types and the impending patent expiration of numerous blockbuster oncology biologics, which creates opportunities for lower-cost alternatives.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.54 Billion
Market Size 2030
USD 6.79 Billion
CAGR 2025-2030
6.94%
Fastest Growing Segment
Lung Cancer
Largest Market
North America
Key Market Drivers
The increasing global incidence of cancer serves as a primary catalyst for the oncology biosimilars market, generating substantial demand for effective yet affordable treatment solutions. As the worldwide cancer burden rises, healthcare systems are compelled to seek cost-efficient therapeutic alternatives to manage growing patient populations and control expenditures. This rising prevalence directly drives the necessity for accessible oncology therapies, with biosimilars playing a pivotal role in expanding treatment access.
Key Market Challenges
A significant challenge impeding the broader expansion of the Global Oncology Biosimilars Market is the substantial investment and intricate scientific expertise required for biosimilar development and manufacturing processes, alongside the necessity for extensive regulatory validation. This inherent complexity and considerable financial outlay directly deter potential manufacturers and prolong the market entry of oncology biosimilar products. The development pathway demands rigorous analytical characterization, preclinical evaluation, and clinical trials to establish biosimilarity to the original biologic, which is both capital-intensive and time-consuming.
This challenging development environment limits the number of pharmaceutical companies capable of undertaking such programs, especially for complex oncology biologics. Consequently, many reference products, even after patent expiration, do not face biosimilar competition.
Key Market Trends
The growing acceptance and trust in clinical settings significantly influences the global oncology biosimilars market by fostering greater confidence among healthcare professionals and patients. This increased assurance directly translates into higher adoption rates for biosimilar treatments. According to the Association for Accessible Medicines, biosimilar medicines generated $20.2 billion in savings in 2024 alone, highlighting their crucial economic value which underpins broader acceptance. Furthermore, a survey conducted on behalf of the Alliance for Safe Biologic Medicines in August 2024, revealed that 88% of physicians agree switching studies enhance their confidence in the safety of transitioning patients from an originator medicine to an interchangeable biosimilar. This robust physician confidence is paramount for overcoming historical skepticism and driving market penetration.
Key Market Players
Teva Pharmaceuticals Industries Ltd.
STADA Arzneimittel AG
Shanghai Henlius Biotech, Inc.
Sandoz Group AG
Samsung Bioepis NL B.V.
Pfizer Inc.
Ligand Pharmaceuticals Inc.
Mylan Inc.
Innovent Biologics (USA), Inc.
Celltrion Inc.
Report Scope:
In this report, the Global Oncology Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Oncology Biosimilars Market, By Drug Class:
Monoclonal Antibodies
G-CSF
Hematopoietic Agents
Others
Oncology Biosimilars Market, By Type of Cancer:
Breast Cancer
Lung Cancer
Stomach Cancer
Prostate Cancer
Cervical Cancer
Blood Cancer
Brain Cancer
Others
Oncology Biosimilars Market, By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Oncology Biosimilars Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Oncology Biosimilars Market.
Available Customizations:
Global Oncology Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Biosimilars Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Oncology Biosimilars Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Type of Cancer
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Biosimilars Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Type of Cancer
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Oncology Biosimilars Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Type of Cancer
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Oncology Biosimilars Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Type of Cancer
6.3.3.2.3. By Distribution Channel
7. Europe Oncology Biosimilars Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type of Cancer
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Biosimilars Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Type of Cancer
7.3.1.2.3. By Distribution Channel
7.3.2. France Oncology Biosimilars Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Type of Cancer
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Oncology Biosimilars Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Type of Cancer
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Oncology Biosimilars Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Type of Cancer
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Oncology Biosimilars Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Type of Cancer
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Oncology Biosimilars Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type of Cancer
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Oncology Biosimilars Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Type of Cancer
8.3.1.2.3. By Distribution Channel
8.3.2. India Oncology Biosimilars Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Type of Cancer
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Oncology Biosimilars Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Type of Cancer
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Oncology Biosimilars Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Type of Cancer
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Oncology Biosimilars Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Type of Cancer
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Oncology Biosimilars Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Type of Cancer
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Oncology Biosimilars Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Type of Cancer
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Oncology Biosimilars Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Type of Cancer
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Oncology Biosimilars Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Type of Cancer
9.3.3.2.3. By Distribution Channel
10. South America Oncology Biosimilars Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Type of Cancer
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Oncology Biosimilars Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Type of Cancer
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Oncology Biosimilars Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Type of Cancer
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Oncology Biosimilars Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Type of Cancer
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Oncology Biosimilars Market: SWOT Analysis
